pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 6·1 min read
save

Centene reports strong enrollment growth but modest scale for its ICHRA offering

Aug 6, 2026·read at Endpoints ↗EarningsPositive

Centene's chief executive Sarah London said the company's individual coverage health reimbursement arrangement (ICHRA) business is experiencing a strong enrollment growth rate, though the total number of participants remains modest.

ICHRA plans let employers reimburse employees for individual health insurance premiums, offering a flexible alternative to traditional group coverage.

The comments were made during Centene's recent earnings call, highlighting the insurer's focus on expanding this newer product line despite its still‑small scale.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Fixing the mess under ICHRA’s hood”

read at Endpoints ↗
79 words · retrieved Aug 6
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoAnother Novartis failure; Novo drops the ‘Nordisk’; and moreEndpoints
  • 2d agoAll 50 states sign up for most favored nation prices under Medicaid, Trump saysEndpoints
  • 2d agoFDA approves Lilly's oral SERD combo for second-line breast cancer therapyEndpoints
  • 2d agoPost-Hoc Live: The China Biotech Debate goes to WashingtonEndpoints
  • 2d agoCHMP backs Novo’s hemophilia A drug and seven other medicinesEndpoints